ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02561195
Recruitment Status : Active, not recruiting
First Posted : September 25, 2015
Results First Posted : March 30, 2018
Last Update Posted : August 9, 2018
Sponsor:
Information provided by (Responsible Party):
Pfizer

Brief Summary:
This study will investigate a Clostridium difficile vaccine in healthy adults aged 65-85 years. Each subject will initially receive 3 doses of vaccine on 1 of 2 vaccination schedules. The study will assess the safety and tolerability of the vaccine as well as the subjects' immune response to the vaccine. One year after the third dose subjects that did not receive placebo will be randomized to receive a fourth dose. Subjects will be followed for up to 4 years after their third vaccination.

Condition or disease Intervention/treatment Phase
Clostridium Difficile Associated Disease Biological: Clostridium difficile Vaccine Biological: Placebo Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 855 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase 2, Placebo-controlled, Randomized, Observer-blinded Study To Evaluate The Safety, Tolerability, And Immunogenicity Of Two 3-dose Regimens Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 To 85 Years
Actual Study Start Date : July 16, 2015
Actual Primary Completion Date : March 7, 2017
Estimated Study Completion Date : March 23, 2020

Arm Intervention/treatment
Experimental: Low-dose C. difficile Vaccine (accelerated schedule) Biological: Clostridium difficile Vaccine
0.5 mL intramuscular injection.

Experimental: High-dose C. difficile Vaccine (accelerated schedule) Biological: Clostridium difficile Vaccine
0.5 mL intramuscular injection.

Placebo Comparator: Placebo (accelerated schedule) Biological: Placebo
0.5 mL intramuscular injection

Experimental: Low-dose C. difficile Vaccine (non-accelerated schedule) Biological: Clostridium difficile Vaccine
0.5 mL intramuscular injection.

Experimental: High-Dose C. difficile Vaccine (non-accelerated schedule) Biological: Clostridium difficile Vaccine
0.5 mL intramuscular injection.

Placebo Comparator: Placebo (non-accelerated schedule) Biological: Placebo
0.5 mL intramuscular injection




Primary Outcome Measures :
  1. Day 1, 8 and 30 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin A at Day 37 [ Time Frame: Day 37 (7 days after Vaccination 3 of Day 1, 8 and 30 regimen) ]
    Toxin A antibodies were measured using neutralization assay.

  2. Month 0, 1 and 6 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin A at Month 7 [ Time Frame: Month 7 (1 month after Vaccination 3 of Month 0, 1 and 6 regimen) ]
    Toxin A antibodies were measured using neutralization assay.

  3. Day 1, 8 and 30 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin B at Day 37 [ Time Frame: Day 37 (7 days after Vaccination 3 of Day 1, 8 and 30 regimen) ]
    Toxin B antibodies were measured using neutralization assay.

  4. Month 0, 1 and 6 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin B at Month 7 [ Time Frame: Month 7 (1 month after Vaccination 3 of Month 0, 1 and 6 regimen) ]
    Toxin B antibodies were measured using neutralization assay.

  5. Day 1, 8 and 30 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Both Toxin A and Toxin B at Day 37 [ Time Frame: Day 37 (7 days after Vaccination 3 of Day 1, 8 and 30 regimen) ]
    Toxin A and toxin B antibodies were measured using neutralization assay.

  6. Month 0, 1 and 6 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Both Toxin A and Toxin B at Month 7 [ Time Frame: Month 7 (1 month after Vaccination 3 of Month 0, 1 and 6 regimen) ]
    Toxin A and toxin B antibodies were measured using neutralization assay.

  7. Day 1, 8 and 30 Regimen: Percentage of Participants With Local Reactions by Severity Within 7 Days After Vaccination 1 [ Time Frame: within 7 days After Vaccination 1 ]
    Local reactions included pain at injection site, swelling and redness collected by using an electronic diary (e-diary). Pain was graded as: mild (grade 1) (did not interfere with activity), moderate (grade 2)(interfered with activity), severe (grade 3) (prevented daily activity) and grade 4 (emergency room visit or hospitalization). Redness and swelling were graded as: mild (2.5-5.0 centimeter [cm]), moderate (>5.0 to 10.0 cm), severe (>10.0 cm) and grade 4 (necrosis).

  8. Month 0, 1 and 6 Regimen: Percentage of Participants With Local Reactions by Severity Within 14 Days After Vaccination 1 [ Time Frame: within 14 days After Vaccination 1 ]
    Local reactions included pain at injection site, swelling and redness collected by using an electronic diary (e-diary). Pain was graded as: mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and grade 4 (emergency room visit or hospitalization). Redness and swelling were graded as: mild (2.5-5.0 cm), moderate (>5.0 to 10.0 cm), severe (>10.0 cm) and grade 4 (necrosis).

  9. Day 1, 8 and 30 Regimen: Percentage of Participants With Local Reactions by Severity Within 14 Days After Vaccination 2 [ Time Frame: within 14 days After Vaccination 2 ]
    Local reactions included pain at injection site, swelling and redness collected by using an electronic diary (e-diary). Pain was graded as: mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and grade 4 (emergency room visit or hospitalization). Redness and swelling were graded as: mild (2.5-5.0 cm), moderate (>5.0 to 10.0 cm), severe (>10.0 cm) and grade 4 (necrosis).

  10. Month 0, 1 and 6 Regimen: Percentage of Participants With Local Reactions by Severity Within 14 Days After Vaccination 2 [ Time Frame: within 14 days after Vaccination 2 ]
    Local reactions included pain at injection site, swelling and redness collected by using an electronic diary (e-diary). Pain was graded as: mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and grade 4 (emergency room visit or hospitalization). Redness and swelling were graded as: mild (2.5-5.0 cm), moderate (>5.0 to 10.0 cm), severe (>10.0 cm) and grade 4 (necrosis).

  11. Day 1, 8 and 30 Regimen: Percentage of Participants With Local Reactions by Severity Within 14 Days After Vaccination 3 [ Time Frame: within 14 days after Vaccination 3 ]
    Local reactions included pain at injection site, swelling and redness collected by using an electronic diary (e-diary). Pain was graded as: mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and grade 4 (emergency room visit or hospitalization). Redness and swelling were graded as: mild (2.5-5.0 cm), moderate (>5.0 to 10.0 cm), severe (>10.0 cm) and grade 4 (necrosis).

  12. Month 0, 1 and 6 Regimen: Percentage of Participants With Local Reactions by Severity Within 14 Days After Vaccination 3 [ Time Frame: within 14 days after Vaccination 3 ]
    Local reactions included pain at injection site, swelling and redness collected by using an electronic diary (e-diary). Pain was graded as: mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and grade 4 (emergency room visit or hospitalization). Redness and swelling were graded as: mild (2.5-5.0 cm), moderate (>5.0 to 10.0 cm), severe (>10.0 cm) and grade 4 (necrosis).

  13. Day 1, 8 and 30 Regimen: Percentage of Participants With Systemic Events by Severity Within 7 Days After Vaccination 1 [ Time Frame: within 7 days after Vaccination 1 ]
    Systemic events included fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, new or worsening joint pain and were recorded by using an e-diary. Fever was graded as mild (38.0 to 38.4 degree Celsius (C)), moderate (38.5 to 38.9 degree C), severe (39.0 to 40.0 degree C), grade 4 (>40.0 degree C). Vomiting was graded as mild (1-2 times in 24 hours), moderate (>2 times in 24 hours), severe (required intravenous hydration) and grade 4 (hospitalization for hypotensive shock). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours), severe (>=6 stools in 24 hours) and grade 4 (hospitalization). Headache, fatigue, new or worsening muscle pain and new or worsening joint pain was graded as mild (no interference with activity), moderate (some interference with activity), severe (prevents daily activity) and grade 4 (hospitalization).

  14. Month 0, 1 and 6 Regimen: Percentage of Participants With Systemic Events by Severity Within 14 Days After Vaccination 1 [ Time Frame: within 14 days after Vaccination 1 ]
    Systemic events included fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, new or worsening joint pain and were recorded by using an e-diary. Fever was graded as mild (38.0 to 38.4 C), moderate (38.5 to 38.9 degree C), severe (39.0 to 40.0 degree C), grade 4 (>40.0 degree C). Vomiting was graded as mild (1-2 times in 24 hours), moderate (>2 times in 24 hours), severe (required intravenous hydration) and grade 4 (hospitalization for hypotensive shock). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours), severe (>=6 stools in 24 hours) and grade 4 (hospitalization). Headache, fatigue, new or worsening muscle pain and new or worsening joint pain was graded as mild (no interference with activity), moderate (some interference with activity), severe (prevents daily activity) and grade 4 (hospitalization).

  15. Day 1, 8 and 30 Regimen: Percentage of Participants With Systemic Events by Severity Within 14 Days After Vaccination 2 [ Time Frame: within 14 days after Vaccination 2 ]
    Systemic events included fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, new or worsening joint pain and were recorded by using an e-diary. Fever was graded as mild (38.0 to 38.4 C), moderate (38.5 to 38.9 degree C), severe (39.0 to 40.0 degree C), grade 4 (>40.0 degree C). Vomiting was graded as mild (1-2 times in 24 hours), moderate (>2 times in 24 hours), severe (required intravenous hydration) and grade 4 (hospitalization for hypotensive shock). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours), severe (>=6 stools in 24 hours) and grade 4 (hospitalization). Headache, fatigue, new or worsening muscle pain and new or worsening joint pain was graded as mild (no interference with activity), moderate (some interference with activity), severe (prevents daily activity) and grade 4 (hospitalization).

  16. Month 0, 1 and 6 Regimen: Percentage of Participants With Systemic Events by Severity Within 14 Days After Vaccination 2 [ Time Frame: within 14 days after Vaccination 2 ]
    Systemic events included fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, new or worsening joint pain and were recorded by using an e-diary. Fever was graded as mild (38.0 to 38.4 C), moderate (38.5 to 38.9 degree C), severe (39.0 to 40.0 degree C), grade 4 (>40.0 degree C). Vomiting was graded as mild (1-2 times in 24 hours), moderate (>2 times in 24 hours), severe (required intravenous hydration) and grade 4 (hospitalization for hypotensive shock). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours), severe (>=6 stools in 24 hours) and grade 4 (hospitalization). Headache, fatigue, new or worsening muscle pain and new or worsening joint pain was graded as mild (no interference with activity), moderate (some interference with activity), severe (prevents daily activity) and grade 4 (hospitalization).

  17. Day 1, 8 and 30 Regimen: Percentage of Participants With Systemic Events by Severity Within 14 Days After Vaccination 3 [ Time Frame: within 14 days after Vaccination 3 ]
    Systemic events included fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, new or worsening joint pain and were recorded by using an e-diary. Fever was graded as mild (38.0 to 38.4 C), moderate (38.5 to 38.9 degree C), severe (39.0 to 40.0 degree C), grade 4 (>40.0 degree C). Vomiting was graded as mild (1-2 times in 24 hours), moderate (>2 times in 24 hours), severe (required intravenous hydration) and grade 4 (hospitalization for hypotensive shock). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours), severe (>=6 stools in 24 hours) and grade 4 (hospitalization). Headache, fatigue, new or worsening muscle pain and new or worsening joint pain was graded as mild (no interference with activity), moderate (some interference with activity), severe (prevents daily activity) and grade 4 (hospitalization).

  18. Month 0, 1 and 6 Regimen: Percentage of Participants With Systemic Events by Severity Within 14 Days After Vaccination 3 [ Time Frame: within 14 days after Vaccination 3 ]
    Systemic events included fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, new or worsening joint pain and were recorded by using an e-diary. Fever was graded as mild (38.0 to 38.4 C), moderate (38.5 to 38.9 degree C), severe (39.0 to 40.0 degree C), grade 4 (>40.0 degree C). Vomiting was graded as mild (1-2 times in 24 hours), moderate (>2 times in 24 hours), severe (required intravenous hydration) and grade 4 (hospitalization for hypotensive shock). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours), severe (>=6 stools in 24 hours) and grade 4 (hospitalization). Headache, fatigue, new or worsening muscle pain and new or worsening joint pain was graded as mild (no interference with activity), moderate (some interference with activity), severe (prevents daily activity) and grade 4 (hospitalization).

  19. Day 1, 8 and 30 Regimen: Percentage of Participants With Treatment Emergent Adverse Events (AEs) [ Time Frame: From Vaccination 1 up to 28 days after Vaccination 3 (Day 58) ]
    An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose of study drug that were absent before treatment or that worsened relative to pretreatment state.

  20. Month 0, 1 and 6 Regimen: Percentage of Participants With Treatment Emergent Adverse Events (AEs) [ Time Frame: From Vaccination 1 up to 28 days after Vaccination 3 (Day 208) ]
    An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose of study drug that were absent before treatment or that worsened relative to pretreatment state.

  21. Day 1, 8 and 30 Regimen: Percentage of Participants With Treatment Emergent Serious Adverse Events (SAEs) [ Time Frame: From Vaccination 1 up to 6 months after Vaccination 3 (Month 7) ]
    An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. Treatment-emergent serious adverse events are events between first dose of study drug and up to 6 months after last dose of study drug that were absent before treatment or that worsened relative to pretreatment state.

  22. Month 0, 1 and 6 Regimen: Percentage of Participants With Treatment Emergent Serious Adverse Events (SAEs) [ Time Frame: From Vaccination 1 up to 6 months after Vaccination 3 (Month 12) ]
    An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. Treatment-emergent serious adverse events are events between first dose of study drug and up to 6 months after last dose of study drug that were absent before treatment or that worsened relative to pretreatment state.


Secondary Outcome Measures :
  1. Day 1, 8 and 30 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin A at Day 1, 8, 15, 30, and Month 2, 4, 7, 13 [ Time Frame: Day 1, 8, 15, 30 and Month 2, 4, 7, 13 ]
    Toxin A antibodies were measured using neutralization assay.

  2. Day 1, 8 and 30 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin B at Day 1, 8, 15, 30 and Month 2, 4, 7, 13 [ Time Frame: Day 1, 8, 15, 30 and Month 2, 4, 7, 13 ]
    Toxin B antibodies were measured using neutralization assay.

  3. Day 1, 8 and 30 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Both Toxin A and Toxin B at Day 1, 8, 15, 30 and Month 2, 4, 7, 13 [ Time Frame: Day 1, 8, 15, 30 and Month 2, 4, 7, 13 ]
    Toxin A and toxin B antibodies were measured using neutralization assay.

  4. Month 0, 1 and 6 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin A at Day 1, 30, 37, 187 and Month 2, 6, 12, 18 [ Time Frame: Day 1, 30, 37, 187 and Month 2, 6, 12, 18 ]
    Toxin A antibodies were measured using neutralization assay.

  5. Month 0, 1 and 6 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for for Toxin B at Day 1, 30, 37, 187 and Month 2, 6, 12, 18 [ Time Frame: Day 1, 30, 37, 187 and Month 2, 6, 12, 18 ]
    Toxin B antibodies were measured using neutralization assay.

  6. Month 0, 1 and 6 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Both Toxin A and Toxin B at Day 1, 30, 37, 187 and Month 2, 6, 12, 18 [ Time Frame: Day 1, 30, 37, 187 and Month 2, 6, 12, 18 ]
    Toxin A and toxin B antibodies were measured using neutralization assay.

  7. Day 1, 8 and 30 Regimen: Geometric Mean Concentration of Toxin A Specific Neutralizing Antibody Levels at Day 1, 8, 15, 30, 37 and Month 2, 4, 7, 13 [ Time Frame: Day 1, 8, 15, 30, 37 and Month 2, 4, 7, 13 ]
    Geometric mean concentration (GMC) of toxin A specific antibody levels was calculated using back transformations of the logarithmically transformed means of assay results. Confidence interval (CI) for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of concentrations.

  8. Day 1, 8 and 30 Regimen: Geometric Mean Concentration of Toxin B Specific Neutralizing Antibody Levels at Day 1, 8, 15, 30, 37 and Month 2, 4, 7, 13 [ Time Frame: Day 1, 8, 15, 30, 37 and Month 2, 4, 7, 13 ]
    GMC of toxin B specific antibody levels was calculated using back transformations of the logarithmically transformed means of assay results. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of concentrations.

  9. Month 0, 1 and 6 Regimen: Geometric Mean Concentration of Toxin A Specific Neutralizing Antibody Levels at Day 1, 30, 37, 187 and Month 2, 6, 7, 12, 18 [ Time Frame: Day 1, 30, 37, 187 and Month 2, 6, 7, 12, 18 ]
    GMC of toxin A specific antibody levels was calculated using back transformations of the logarithmically transformed means of assay results. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of concentrations.

  10. Month 0, 1 and 6 Regimen: Geometric Mean Concentration of Toxin B Specific Neutralizing Antibody Levels at Day 1, 30, 37, 187 and Month 2, 6, 7, 12, 18 [ Time Frame: Day 1, 30, 37, 187 and Month 2, 6, 7, 12, 18 ]
    GMC of toxin B specific antibody levels was calculated using back transformations of the logarithmically transformed means of assay results. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of concentrations.

  11. Day 1, 8 and 30 Regimen: Geometric Mean Fold Rise in Toxin A Specific Neutralizing Antibody Levels From Baseline at Day 8, 15, 30, 37 and Month 2, 4, 7, 13 [ Time Frame: Day 8, 15, 30, 37 and Month 2, 4, 7, 13 ]
    Geometric mean fold rise (GMFR) in toxin A specific antibody levels was calculated using back transformations of the logarithmically transformed means of fold rise from baseline with assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.

  12. Day 1, 8 and 30 Regimen: Geometric Mean Fold Rise in Toxin B Specific Neutralizing Antibody Levels From Baseline at Day 8, 15, 30, 37 and Month 2, 4, 7, 13 [ Time Frame: Day 8, 15, 30, 37 and Month 2, 4, 7, 13 ]
    GMFR in toxin B specific antibody levels was calculated using back transformations of the logarithmically transformed means of fold rise from baseline with assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.

  13. Month 0, 1 and 6 Regimen: Geometric Mean Fold Rise in Toxin A Specific Neutralizing Antibody Levels From Baseline at Day 30, 37, 187 and Month 2, 6, 7, 12, 18 [ Time Frame: Day 30, 37, 187 and Month 2, 6, 7, 12, 18 ]
    GMFR in toxin A specific antibody levels was calculated using back transformations of the logarithmically transformed means of fold rise from baseline with assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.

  14. Month 0, 1 and 6 Regimen: Geometric Mean Fold Rise in Toxin B Specific Neutralizing Antibody Levels From Baseline at Day 30, 37, 187 and Month 2, 6, 7, 12, 18 [ Time Frame: Day 30, 37, 187 and Month 2, 6, 7, 12, 18 ]
    GMFR for toxin B specific antibody levels was calculated using back transformations of the logarithmically transformed means of fold rise from baseline with assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.

  15. Day 1, 8 and 30 Regimen: Percentage of Participants Achieving >=4, >=8, >=16 and >=32 Fold Rise From Baseline in Toxin A Specific Antibody Levels at Day 8, 15, 30, 37 and Month 2, 4, 7, 13 [ Time Frame: Day 8, 15, 30, 37 and Month 2, 4, 7, 13 ]
    Toxin A antibodies were measured using neutralization assay.

  16. Day 1, 8 and 30 Regimen: Percentage of Participants Achieving >=4, >=8, >=16 and >=32 Fold Rise From Baseline in Toxin B Specific Antibody Levels at Day 8, 15, 30, 37 and Month 2, 4, 7, 13 [ Time Frame: Day 8, 15, 30, 37 and Month 2, 4, 7, 13 ]
    Toxin B antibodies were measured using neutralization assay.

  17. Day 1, 8 and 30 Regimen: Percentage of Participants Achieving>=4,>=8,>=16,>=32 Fold Rise From Baseline in Both Toxin A and Toxin B Specific Antibody Levels at Day 8, 15, 30, 37 and Month 2, 4, 7, 13 [ Time Frame: Day 8, 15, 30, 37 and Month 2, 4, 7, 13 ]
    Toxin A and toxin B antibodies were measured using neutralization assay.

  18. Month 0, 1 and 6 Regimen: Percentage of Participants Achieving >=4, >=8, >=16 and >=32 Fold Rise From Baseline in Toxin A Specific Antibody Levels at Day 30, 37, 187 and Month 2, 6, 7, 12, 18 [ Time Frame: Day 30, 37, 187 and Month 2, 6, 7, 12, 18 ]
    Toxin A antibodies were measured using neutralization assay.

  19. Month 0, 1 and 6 Regimen: Percentage of Participants Achieving >=4, >=8, >=16 and >=32 Fold Rise From Baseline in Toxin B Specific Antibody Levels at Day 30, 37, 187 and Month 2, 6, 7, 12, 18 [ Time Frame: Day 30, 37, 187 and Month 2, 6, 7, 12, 18 ]
    Toxin A antibodies were measured using neutralization assay.

  20. Month 0, 1 and 6 Regimen: Percentage of Participants Achieving>=4,>=8,>=16,>=32 Fold Rise From Baseline in Both Toxin A and Toxin B Antibody Levels at Day 30, 37, 187 and Month 2, 6, 7, 12, 18 [ Time Frame: Day 30, 37, 187 and Month 2, 6, 7, 12, 18 ]
    Toxin A and toxin B antibodies were measured using neutralization assay.

  21. Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin A at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 [ Time Frame: Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 ]
  22. Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin B at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 [ Time Frame: Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 ]
  23. Percentage of Participants Achieving Prespecified Antibody Titer Level for Both Toxin A and Toxin B at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 [ Time Frame: Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 ]
  24. Geometric Mean Concentration for Toxin A Specific Neutralizing Antibody Levels at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 [ Time Frame: Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 ]
  25. Geometric Mean Concentration for Toxin B Specific Neutralizing Antibody Levels at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 [ Time Frame: day 8, 30; month 6, 12, 18, 24, 30, 36 after Vaccination 4 ]
  26. Geometric Mean Fold Rise in Toxin A Specific Neutralizing Antibody Levels From Baseline at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 [ Time Frame: Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 ]
  27. Geometric Mean Fold Rise in Toxin B Specific Neutralizing Antibody Levels From Baseline at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 [ Time Frame: Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 ]
  28. Percentage of Participants Achieving >=4, >=8, >=16 and >=32 Fold Rise From Baseline in Toxin A Specific Antibody Levels at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 [ Time Frame: Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 ]
  29. Percentage of Participants Achieving >=4, >=8, >=16 and >=32 Fold Rise From Baseline in Toxin B Specific Antibody Levels at Day 8, 30, Month 6, 12, 18, 24, 30 and 36 [ Time Frame: Day 8, 30 and Month 6, 12, 18, 24, 30, 36 ]
  30. Percentage of Participants Achieving>=4,>=8,>=16,>=32 Fold Rise From Baseline in Both Toxin A and Toxin B Antibody Levels at Day 8, 30, Month 6, 12, 18, 24, 30 and 36 [ Time Frame: Day 8, 30 and Month 6, 12, 18, 24, 30, 36 ]
  31. Percentage of Participants With Local Reactions by Severity Within 14 Days of Vaccination 4 [ Time Frame: within 14 days of Vaccination 4 ]
  32. Percentage of Participants With Systemic Events by Severity Within 14 Days of Vaccination 4 [ Time Frame: within 14 days of Vaccination 4 ]
  33. Percentage of Participants With Treatment Emergent Adverse Events (AEs) [ Time Frame: From Vaccination 4 up to 28 days after Vaccination 4 ]
  34. Percentage of Participants With Treatment Emergent Serious Adverse Events (SAEs) [ Time Frame: From Vaccination 4 up to 6 months after Vaccination 4 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   65 Years to 85 Years   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male and female subjects
  • Aged 65 to 85 years

Additional Inclusion Criteria for the extension Stage:

  • Receipt of all 3 doses of C difficile vaccine (100 µg or 200 µg antigen dose level) in the original portion of the study.

Exclusion Criteria:

  • Proven or suspected prior episode of Clostridium difficile associated diarrhea
  • Unstable chronic medical condition
  • Disease requiring significant change in therapy or hospitalization for worsening disease within 8 weeks before receipt of study vaccine
  • Serious chronic disorders
  • Congenital or acquired immunodeficiency disorders
  • Rheumatologic disorders or other illnesses requiring chronic treatment with known immunosuppressant medications.
  • Active or treated leukemia or lymphoma or bone marrow disorder
  • Any contraindication to vaccination or vaccine components including previous anaphylactic reaction to any vaccine or vaccine-related components

Additional Exclusion Criteria for the Extension Stage:

  • Subjects originally randomized to placebo during the original portion of the study.
  • Subjects who have already completed Visit 9 prior to study unblinding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02561195


Locations
United States, Florida
Avail Clinical Research, LLC
DeLand, Florida, United States, 32720
QPS-MRA, LLC (Broward Research Group)
Hollywood, Florida, United States, 33024
QPS-MRA, LLC (Miami Research Associates)
South Miami, Florida, United States, 33143
United States, Hawaii
East-West Medical Research Institute
Honolulu, Hawaii, United States, 96814
United States, Kansas
Vince & Associates Clinical Research, Inc.
Overland Park, Kansas, United States, 66212
Vince & Associates Clinical Research, Inc
Overland Park, Kansas, United States, 66212
United States, Nebraska
Meridian Clinical Research, LLC
Omaha, Nebraska, United States, 68134
United States, Nevada
Clinical Research Center of Nevada LLC
Las Vegas, Nevada, United States, 89104
United States, North Carolina
Wake Research Associates, LLC
Raleigh, North Carolina, United States, 27612
PMG Research of Wilmington, LLC
Wilmington, North Carolina, United States, 28401
United States, Ohio
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45206
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229
United States, Texas
Benchmark Research
Austin, Texas, United States, 78705
Texas Center For Drug Development, Inc.
Houston, Texas, United States, 77081
Clinical Trials of Texas, Inc.
San Antonio, Texas, United States, 78229
United States, Utah
J. Lewis Research, Inc. / Foothill Family Clinic
Salt Lake City, Utah, United States, 84109
J. Lewis Research, Inc. / Foothill Family Clinic South
Salt Lake City, Utah, United States, 84121
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  Study Documents (Full-Text)

Documents provided by Pfizer:
Statistical Analysis Plan  [PDF] June 17, 2016
Study Protocol  [PDF] April 4, 2017


Additional Information:
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT02561195     History of Changes
Other Study ID Numbers: B5091009
First Posted: September 25, 2015    Key Record Dates
Results First Posted: March 30, 2018
Last Update Posted: August 9, 2018
Last Verified: July 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Pfizer:
Clostridium difficile, Vaccine.

Additional relevant MeSH terms:
Vaccines
Immunologic Factors
Physiological Effects of Drugs